Clinical trials: Prostate Cancer Patients
- Condition Prostate Cancer Patients
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Prostatic Neoplasms
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
- Trial name
- NCT00313781
- Testing
- CP-751,871, docetaxel, prednisone
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Prostate Cancer
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
- Trial name
- NCT01547299
- Testing
- Enzalutamide, Leuprolide, Dutasteride
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Pfizer
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Primary Objective: To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan…
- Trial name
- CARD (NCT02485691)
- Testing
- cabazitaxel XRP6258, enzalutamide, abiraterone acetate
- Where
- 65 sites in Austria, Belgium and 11 more
- Volunteers
- 255 people
- Sponsor
- Sanofi
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer
Study to Evaluate CCS1477 in Advanced Tumours
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT03568656
- Testing
- CCS1477, Abiraterone acetate, Enzalutamide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 219 people
- Sponsor
- CellCentric Ltd.
Prostate Cancer
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.
- Trial name
- ENACT (NCT02799745)
- Testing
- Enzalutamide, Active Surveillance
- Where
- 54 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enrollment in this study was discontinued by the Sponsor on 01 Dec 2023.
- Trial name
- NCT05605964
- Testing
- Relugolix, Leuprolide Acetate
- Where
- 108 sites in United States
- Volunteers
- 387 people
- Sponsor
- Sumitomo Pharma America, Inc.
Prostatic Neoplasms
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
The primary objective of this trial is to estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic…
- Trial name
- NCT00706628
- Testing
- BIBF 1120, BIBW 2992, Sequential BIBF 1120 + BIBW 2992
- Where
- 9 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Boehringer Ingelheim
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Hormone Treatment-naïve Participants With Prostate Cancer
A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.
- Trial name
- NCT02141659
- Testing
- TAK-385
- Where
- 6 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Takeda
Prostate Cancer
An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate
The primary objective was to evaluate efficacy of a single dose of Liproca Depot in patients with localized prostate cancer. Primary efficacy variable was the proportion of patients showing PSA nadir.
- Trial name
- 2-HOF (NCT00913263)
- Testing
- 2-hydroxyflutamide (2-HOF) [Liproca Depot], 2-Hydroxyflutamide
- Where
- 2 sites in Finland
- Volunteers
- 24 people
- Sponsor
- Lidds AB
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
This is an open-label, single-arm, multi-center extension study to evaluate safety in patients with mCRPC of YONSA 500 mg (4 x 125 mg qd) with methylprednisolone (4 mg bid).
- Trial name
- NCT02962284
- Testing
- abiraterone acetate with Methylprednisolone
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
The primary purpose of this study is to evaluate the efficacy of triptorelin embonate 22.5 mg 6-month formulation administered by the subcutaneous (under the skin) route in: achieving castrate levels of testosterone (< 1.735…
- Trial name
- NCT01656161
- Testing
- Triptorelin embonate 22.5 mg
- Where
- 10 sites in South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination…
- Trial name
- NCT03437941
- Testing
- Exicorilant, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Corcept Therapeutics
Prostate Cancer
A Trial of Degarelix in Patients With Prostate Cancer
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
- Trial name
- NCT00946920
- Testing
- Degarelix, Goserelin acetate
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 859 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy.
- Trial name
- ANABRAQ (NCT01374087)
- Testing
- Triptorelin 22.5 mg, Brachytherapy
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Ipsen
Cancer of the Prostate
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
The main aim is to assess the impact of using 18F-fluciclovine (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being…
- Trial name
- FALCON (NCT02578940)
- Testing
- 18F-Fluciclovine PET CT
- Where
- 7 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was…
- Trial name
- NCT00117312
- Testing
- Degarelix
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT02217566
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 4 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic…
- Trial name
- NCT01193244
- Testing
- Orteronel, Prednisone
- Where
- 240 sites in United States, Australia and 38 more
- Volunteers
- 1,560 people
- Sponsor
- Millennium Pharmaceuticals, Inc.